MENU

Published on 29/05/2020 4:09:34 PM | Source: Reuters

Sun Pharma to conduct clinical trial of pancreatitis drug in COVID-19 patients

Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel  https://t.me/InvestmentGuruIndia 

Download Telegram App before Joining the Channel

BENGALURU  - Drugmaker Sun Pharmaceutical Industries Ltd said on Friday that it received Indian regulatory approval to start clinical trials of pancreatitis drug nafamostat mesilate in COVID-19 patients.

"Nafamostat (has been) identified as a potential candidate for COVID-19 patients by scientists at University of Tokyo and Leibniz Institute for Primate Research, Germany," the company said in a statement.

The University of Tokyo had announced plans for a trial of nafamostat and camostat mesilate, a related drug, starting as early as April 2020.

(Reporting by Anuron Kumar Mitra in Bengaluru; Editing by Anil D'Silva)